Quest PharmaTech Inc. is engaged in the development and commercialization of new pharmaceutical products. The Company’s is developing a series of products for the treatment of cancer and dermatological conditions based on its photodynamic and sonodynamic therapy platform. Quest is developing these compounds as drugs, as well as developing means of activating and delivering them to target tissues. The Company’s lead product, SL017, is a topical formulation indicated for dermatology applications. A second product from the SonoLight platform, SL052, is an injectable formulation that is in late-stage pre-clinical development for prostate cancer treatment. Quest has entered into a license agreement with KMH Co., Ltd ("KMH") to market the Company's hair removal product, SL017, in Asia.
(Source: ARS)
